409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics

• Richard A Morgan,
• David J Rawlings,
• Richard G James,
• Jasmine N Edelstein,
• Tyler F Hill,
• Michael D Leiken,
• Katherine M Molloy,
• Glory Adekanye,
• Caroline Bullock,
• Adam S Lazorchak,
• Ken-Edwin Aryee,
• Sean P Arlauckas

Affiliations

Richard A Morgan

1Be Biopharma, Cambridge, MA, USA

David J Rawlings

2University of Washington, Seattle, WA, USA

Richard G James

2University of Washington, Seattle, WA, USA

Jasmine N Edelstein

1Be Biopharma, Cambridge, MA, USA

Tyler F Hill

2University of Washington, Seattle, WA, USA

Michael D Leiken

1Be Biopharma, Cambridge, MA, USA

Katherine M Molloy

1Be Biopharma, Cambridge, MA, USA

Glory Adekanye

1Be Biopharma, Cambridge, MA, USA

Caroline Bullock

1Be Biopharma, Cambridge, MA, USA

Adam S Lazorchak

1Be Biopharma, Cambridge, MA, USA

Ken-Edwin Aryee

1Be Biopharma, Cambridge, MA, USA

Sean P Arlauckas

1Be Biopharma, Cambridge, MA, USA